Share This Page

 
Now on Twitter!

Follow us: ChinaBio

Site Search

>> Advanced Search

  Quick Search:
 
 

Free Newsletter

  Email address:
   

Free White Paper

AlphaRx Receives SFDA Approval for Topical Arthritis Product

publication date: Dec 7, 2007
View a Printer Friendly version of this page, allowing you to print the page. Send a summary of this page to someone via email.

AlphaRx received approval from the State FDA of China for Indaflex™, a topical arthritis relief product. Indaflex™ is a topical formulation of Indomethacin that is incorporated in a nanotechnology drug delivery system developed by AlphaRx. Previously, Indaflex™ was approved in Mexico. AlphaRx International Holdings (AIH), the Hong Kong affiliate of AlphaRx, will launch Indaflex™ in 2008, and it is already building a plant in China to produce the drug. More details....

Stock Symbols: (OTCBB:ALRX) (NYSE: MRK)




Sorry... this feature or article is only available to subscribers.

>> Learn more about our subscription plans...

>> Free email newsletter...

>> Login...


Login

  

    
   
ChinaBio® Events

ChinaBio® Partnering Forum 2012
May 23-24, 2012
Suzhou, China

>>More events...
Partner Events

China Healthcare Investment Conference 2012
March 13-15, 2012
Shanghai, China


Shanghai CEO Conference
March 28-29, 2012
Shanghai, China

>>More details...
Our Partners
Annual Sponsors
 
Official Partners
 
Supporting Partners
 
Media Partners